Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Geldanamycin |
Synonyms | |
Therapy Description |
Geldanamycin binds to and inhibits HSP90, potentially resulting in decreased tumor cell growth and increased tumor cell apoptosis (PMID: 19850405, PMID: 11927289, PMID: 32573272). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Geldanamycin | HSP90 Inhibitor 35 | Geldanamycin binds to and inhibits HSP90, potentially resulting in decreased tumor cell growth and increased tumor cell apoptosis (PMID: 19850405, PMID: 11927289, PMID: 32573272). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 Q959H JAK2 L983F | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L983F, and Q959H in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 Y931C | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and Y931C in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 L902Q | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L902Q in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 L983F | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F and L983F in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 L902Q JAK2 R938E | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R938E in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 L902Q JAK2 R947Q | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and R947Q in culture (PMID: 39091915). | 39091915 |
JAK2 V617F | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F in culture (PMID: 39091915). | 39091915 |
JAK2 V617F JAK2 L902Q JAK2 E1028K | hematologic cancer | sensitive | Geldanamycin | Preclinical - Cell culture | Actionable | In a preclinical study, Geldanamycin inhibited Stat5 signaling and proliferation in a cell line expressing JAK2 V617F, L902Q, and E1028K in culture (PMID: 39091915). | 39091915 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|